Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2016-04-06 Director's Dealing
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - GK 3 pages 80.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and Corporations Act sections related to director interests. It details changes in securities held by a director, including number of shares and options acquired or disposed, and the nature of these changes. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is not an announcement of a report, nor a full financial or management report, but a specific regulatory filing about insider transactions.
2016-04-06 English
Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial 3 pages 328.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 30 March 2016 from Opthea Limited announcing the completion of patient enrolment for a Phase 1 dose escalation clinical trial of OPT-302 for wet AMD. It provides details about the trial design, patient cohorts, expected reporting timelines for safety and secondary outcomes, and background information about the drug and disease. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is a corporate announcement about clinical trial progress and future data reporting, typical of a capital/financing update or clinical development update. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the announcement focusing on clinical trial progress and milestones, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed content support it being a substantive announcement rather than a brief notice or report publication announcement.
2016-03-29 English
Chairman's Address to the EGM 3 pages 58.4KB
AGM Information Classification · 95% confidence The document is an ASX and media release dated March 7, 2016, containing the Chairman's address to an Extraordinary General Meeting (EGM) of Opthea Limited. It includes introductions of board members, updates on clinical trial progress, strategic reviews, and corporate structure changes. The content focuses on the Chairman's speech and company updates presented at the EGM, rather than detailed financial statements or comprehensive annual reporting. There is no indication of full financial performance data or audit information. The document is clearly related to materials shared during a general meeting, specifically an Extraordinary General Meeting, which aligns with the category for AGM Information (AGM-R). Although it is an EGM, the AGM Information category typically covers presentations and materials shared during general meetings including EGMs. Therefore, the most appropriate classification is AGM Information (AGM-R).
2016-03-06 English
CEO's Presentation to the EGM 19 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Corporate Update' for Opthea Limited, dated around March 7, 2016, coinciding with an Extraordinary General Meeting (EGM). It includes extensive information about the company's clinical programs, financial position, corporate achievements, corporate restructuring, and clinical trial details. The content is structured as a presentation with slides, including forward-looking statements, clinical trial milestones, financial data, and corporate strategy. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a transcript of a call, nor is it a voting result or director dealing report. It is clearly a presentation aimed at investors and stakeholders, likely used in conjunction with the EGM. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2016-03-06 English
Results of the Extraordinary General Meeting 1 page
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 7th March 2016 reporting the results of an Extraordinary General Meeting (EGM). It provides detailed voting results for resolutions including election of directors and issuance of options. The text references proxy votes and compliance with ASX Listing Rule 3.13.2 and Corporations Act section 251AA(1), which are typical for official voting results announcements. The document is short (2350 characters) and focuses solely on the voting outcomes rather than the meeting materials or the meeting itself. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-03-06 English
Half Year Report and Accounts 24 pages 988.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled '31 December 2015 half-year financial report & operational performance' and references the half-year ended 31 December 2015. It includes detailed financial data such as revenues, losses, cash position, net tangible asset backing, and tax benefits. It also contains a Directors' Report, Auditor's Independence Declaration, Financial Statements, Directors' Declaration, and Independent Review Report. The document explicitly states it is a Half-Year Financial Report and includes substantive financial statements and analysis. The length is 15,000 characters, indicating a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2016-02-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.